Stay updated on Lenvatinib and Pembrolizumab in DTC Clinical Trial

Sign up to get notified when there's something new on the Lenvatinib and Pembrolizumab in DTC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Lenvatinib and Pembrolizumab in DTC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3. This appears to be a metadata version change and does not modify core content such as study details or eligibility criteria.
    Difference
    0.0%
    Check dated 2026-03-11T18:55:19.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Site footer updated to Revision: v3.4.2; the government funding-lapse notice and the older Revision: v3.4.1 label were removed.
    Difference
    0.4%
    Check dated 2026-02-11T10:30:57.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    A site-wide notice about a lapse in government funding was added, and the page shows a new revision tag (v3.4.1) replacing the previous (v3.4.0).
    Difference
    0.4%
    Check dated 2026-02-04T10:14:04.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Added UI elements for glossary visibility and new metadata labels (Last Update Submitted that Met QC Criteria, Last Update Posted, Revision: v3.4.0). Removed older metadata labels (Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, Revision: v3.3.4).
    Difference
    0.2%
    Check dated 2026-01-28T04:48:11.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    The page revision was updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T03:20:20.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    Added a dedicated Locations section listing study sites by state (CA, CO, MA, MI, NY, OH, TX) as part of revision 3.3.3 and removed the individual state Location subsections. The HHS Vulnerability Disclosure link was removed in revision 3.3.2.
    Difference
    0.8%
    Check dated 2025-12-23T20:43:37.000Z thumbnail image

Stay in the know with updates to Lenvatinib and Pembrolizumab in DTC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Lenvatinib and Pembrolizumab in DTC Clinical Trial page.